List of Tables
Table 1. Global Rare Biomarkers Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Rare Biomarkers Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Rare Biomarkers Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Rare Biomarkers Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Rare Biomarkers Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Rare Biomarkers Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Rare Biomarkers Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Rare Biomarkers by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rare Biomarkers as of 2024)
Table 11. Global Rare Biomarkers Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Rare Biomarkers Companies Headquarters
Table 13. Global Rare Biomarkers Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Rare Biomarkers Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Rare Biomarkers Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Rare Biomarkers Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Rare Biomarkers Revenue by Application (2026-2031) & (US$ Million)
Table 21. Rare Biomarkers High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Rare Biomarkers Growth Accelerators and Market Barriers
Table 25. North America Rare Biomarkers Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Rare Biomarkers Growth Accelerators and Market Barriers
Table 27. Europe Rare Biomarkers Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Rare Biomarkers Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Rare Biomarkers Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Rare Biomarkers Investment Opportunities and Key Challenges
Table 31. Central and South America Rare Biomarkers Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Rare Biomarkers Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Rare Biomarkers Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Corporation Information
Table 35. Roche Description and Major Businesses
Table 36. Roche Product Features and Attributes
Table 37. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Revenue Proportion by Product in 2024
Table 39. Roche Revenue Proportion by Application in 2024
Table 40. Roche Revenue Proportion by Geographic Area in 2024
Table 41. Roche Rare Biomarkers SWOT Analysis
Table 42. Roche Recent Developments
Table 43. Thermo Fisher Scientific Corporation Information
Table 44. Thermo Fisher Scientific Description and Major Businesses
Table 45. Thermo Fisher Scientific Product Features and Attributes
Table 46. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Thermo Fisher Scientific Revenue Proportion by Product in 2024
Table 48. Thermo Fisher Scientific Revenue Proportion by Application in 2024
Table 49. Thermo Fisher Scientific Revenue Proportion by Geographic Area in 2024
Table 50. Thermo Fisher Scientific Rare Biomarkers SWOT Analysis
Table 51. Thermo Fisher Scientific Recent Developments
Table 52. Abbott Corporation Information
Table 53. Abbott Description and Major Businesses
Table 54. Abbott Product Features and Attributes
Table 55. Abbott Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Abbott Revenue Proportion by Product in 2024
Table 57. Abbott Revenue Proportion by Application in 2024
Table 58. Abbott Revenue Proportion by Geographic Area in 2024
Table 59. Abbott Rare Biomarkers SWOT Analysis
Table 60. Abbott Recent Developments
Table 61. Qiagen Corporation Information
Table 62. Qiagen Description and Major Businesses
Table 63. Qiagen Product Features and Attributes
Table 64. Qiagen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Qiagen Revenue Proportion by Product in 2024
Table 66. Qiagen Revenue Proportion by Application in 2024
Table 67. Qiagen Revenue Proportion by Geographic Area in 2024
Table 68. Qiagen Rare Biomarkers SWOT Analysis
Table 69. Qiagen Recent Developments
Table 70. PerkinElmer Corporation Information
Table 71. PerkinElmer Description and Major Businesses
Table 72. PerkinElmer Product Features and Attributes
Table 73. PerkinElmer Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. PerkinElmer Revenue Proportion by Product in 2024
Table 75. PerkinElmer Revenue Proportion by Application in 2024
Table 76. PerkinElmer Revenue Proportion by Geographic Area in 2024
Table 77. PerkinElmer Rare Biomarkers SWOT Analysis
Table 78. PerkinElmer Recent Developments
Table 79. Merck KGaA Corporation Information
Table 80. Merck KGaA Description and Major Businesses
Table 81. Merck KGaA Product Features and Attributes
Table 82. Merck KGaA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Merck KGaA Recent Developments
Table 84. Bio-Rad Laboratories Corporation Information
Table 85. Bio-Rad Laboratories Description and Major Businesses
Table 86. Bio-Rad Laboratories Product Features and Attributes
Table 87. Bio-Rad Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Bio-Rad Laboratories Recent Developments
Table 89. Enzo Biochem Corporation Information
Table 90. Enzo Biochem Description and Major Businesses
Table 91. Enzo Biochem Product Features and Attributes
Table 92. Enzo Biochem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Enzo Biochem Recent Developments
Table 94. Charles River Laboratories International Corporation Information
Table 95. Charles River Laboratories International Description and Major Businesses
Table 96. Charles River Laboratories International Product Features and Attributes
Table 97. Charles River Laboratories International Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Charles River Laboratories International Recent Developments
Table 99. Eurofins Scientific Corporation Information
Table 100. Eurofins Scientific Description and Major Businesses
Table 101. Eurofins Scientific Product Features and Attributes
Table 102. Eurofins Scientific Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Eurofins Scientific Recent Developments
Table 104. Agilent Technologies Corporation Information
Table 105. Agilent Technologies Description and Major Businesses
Table 106. Agilent Technologies Product Features and Attributes
Table 107. Agilent Technologies Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Agilent Technologies Recent Developments
Table 109. Bruker Corporation Information
Table 110. Bruker Description and Major Businesses
Table 111. Bruker Product Features and Attributes
Table 112. Bruker Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Bruker Recent Developments
Table 114. Siemens Healthineers Corporation Information
Table 115. Siemens Healthineers Description and Major Businesses
Table 116. Siemens Healthineers Product Features and Attributes
Table 117. Siemens Healthineers Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Siemens Healthineers Recent Developments
Table 119. Epigenomics Corporation Information
Table 120. Epigenomics Description and Major Businesses
Table 121. Epigenomics Product Features and Attributes
Table 122. Epigenomics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Epigenomics Recent Developments
Table 124. GE HealthCare Corporation Information
Table 125. GE HealthCare Description and Major Businesses
Table 126. GE HealthCare Product Features and Attributes
Table 127. GE HealthCare Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. GE HealthCare Recent Developments
Table 129. Diaceutics Corporation Information
Table 130. Diaceutics Description and Major Businesses
Table 131. Diaceutics Product Features and Attributes
Table 132. Diaceutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Diaceutics Recent Developments
Table 134. Raw Materials Key Suppliers
Table 135. Distributors List
Table 136. Market Trends and Market Evolution
Table 137. Market Drivers and Opportunities
Table 138. Market Challenges, Risks, and Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Rare Biomarkers Product Picture
Figure 2. Global Rare Biomarkers Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Circulating Cell Free DNA (ccfDNA) Product Picture
Figure 4. Circulating Tumor Cells (CTCs) Product Picture
Figure 5. Exosomes/Extracellular Vesicles Product Picture
Figure 6. Circulating Cell Free RNA (ccfRNA) / miRNA Product Picture
Figure 7. Global Rare Biomarkers Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Diagnostics
Figure 9. Drug Development
Figure 10. Disease Discovery
Figure 11. Other
Figure 12. Rare Biomarkers Report Years Considered
Figure 13. Global Rare Biomarkers Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 15. Global Rare Biomarkers Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Rare Biomarkers Revenue Market Share by Region (2020-2031)
Figure 17. Global Rare Biomarkers Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Circulating Cell Free DNA (ccfDNA) Revenue Market Share by Player in 2024
Figure 20. Circulating Tumor Cells (CTCs) Revenue Market Share by Player in 2024
Figure 21. Exosomes/Extracellular Vesicles Revenue Market Share by Player in 2024
Figure 22. Circulating Cell Free RNA (ccfRNA) / miRNA Revenue Market Share by Player in 2024
Figure 23. Global Rare Biomarkers Revenue Market Share by Type (2020-2031)
Figure 24. Global Rare Biomarkers Revenue Market Share by Application (2020-2031)
Figure 25. North America Rare Biomarkers Revenue YoY (2020-2031) & (US$ Million)
Figure 26. North America Top 5 Players Rare Biomarkers Revenue (US$ Million) in 2024
Figure 27. North America Rare Biomarkers Revenue (US$ Million) by Type (2020 - 2031)
Figure 28. North America Rare Biomarkers Revenue (US$ Million) by Application (2020-2031)
Figure 29. US Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 30. Canada Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 31. Mexico Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 32. Europe Rare Biomarkers Revenue YoY (2020-2031) & (US$ Million)
Figure 33. Europe Top 5 Players Rare Biomarkers Revenue (US$ Million) in 2024
Figure 34. Europe Rare Biomarkers Revenue (US$ Million) by Type (2020-2031)
Figure 35. Europe Rare Biomarkers Revenue (US$ Million) by Application (2020-2031)
Figure 36. Germany Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 37. France Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 38. U.K. Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 39. Italy Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 40. Russia Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Rare Biomarkers Revenue YoY (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Top 8 Players Rare Biomarkers Revenue (US$ Million) in 2024
Figure 43. Asia-Pacific Rare Biomarkers Revenue (US$ Million) by Type (2020-2031)
Figure 44. Asia-Pacific Rare Biomarkers Revenue (US$ Million) by Application (2020-2031)
Figure 45. Indonesia Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 46. Japan Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 47. South Korea Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 48. Australia Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 49. India Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 50. Indonesia Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 51. Vietnam Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 52. Malaysia Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 53. Philippines Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 54. Singapore Rare Biomarkers Revenue (2020-2031) & (US$ Million)
Figure 55. Central and South America Rare Biomarkers Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Central and South America Top 5 Players Rare Biomarkers Revenue (US$ Million) in 2024
Figure 57. Central and South America Rare Biomarkers Revenue (US$ Million) by Type (2020-2031)
Figure 58. Central and South America Rare Biomarkers Revenue (US$ Million) by Application (2020-2031)
Figure 59. Brazil Rare Biomarkers Revenue (2020-2025) & (US$ Million)
Figure 60. Argentina Rare Biomarkers Revenue (2020-2025) & (US$ Million)
Figure 61. Middle East and Africa Rare Biomarkers Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Middle East and Africa Top 5 Players Rare Biomarkers Revenue (US$ Million) in 2024
Figure 63. South America Rare Biomarkers Revenue (US$ Million) by Type (2020-2031)
Figure 64. Middle East and Africa Rare Biomarkers Revenue (US$ Million) by Application (2020-2031)
Figure 65. GCC Countries Rare Biomarkers Revenue (2020-2025) & (US$ Million)
Figure 66. Israel Rare Biomarkers Revenue (2020-2025) & (US$ Million)
Figure 67. Egypt Rare Biomarkers Revenue (2020-2025) & (US$ Million)
Figure 68. South Africa Rare Biomarkers Revenue (2020-2025) & (US$ Million)
Figure 69. Rare Biomarkers Industry Chain Mapping
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
